2009 Annual Report

• Download PDF (1mb)
• Get Acrobat Reader This link will send you outside of the Cangene website

• Contact info for this section
• Print this page

Investor Relations

Directors and Officers

Directors

R. Craig Baxter¹ — Director
Mr. Baxter graduated with a BComm from Concordia University and is a Certified Management Accountant. He has nearly 30 years of business experience, 24 of which have been in the pharmaceutical industry. Mr. Baxter is currently President of Apotex Holdings Inc. and he serves on the board of the Humber River Regional Hospital.

D. Bruce Burlington³ — Director, and HR & Compensation Committee Chair
Dr. Burlington received his medical degree from Louisiana State University in 1976. His extensive background in infectious disease medicine and the U.S. regulatory environment includes 17 years at the U.S. Food and Drug Administration in various positions involving both biologics and generic drugs, and nine years within the Wyeth Pharmaceuticals organization. He retired from his position as Executive Vice President, Business Practices and Compliance at Wyeth and is currently working as a consultant in pharmaceutical development and regulatory affairs.

Jeremy Desai³ — Director
Dr. Desai graduated as a pharmacist in the U.K. and then went on to complete his PhD in Pharmacy and an MBA.  Dr. Desai has nearly 25 years of experience working for both branded and generic pharmaceutical companies. He is currently Executive Vice President Global Research, Development & Quality at Apotex Inc., based in Toronto, Canada.

Philip Johnson^2,3 — Director
Dr. Johnson received his medical degree from the University of North Carolina at Chapel Hill. His extensive medical background, largely in pediatrics and vaccine technology, includes work at the U.S. National Institutes of Health and the Columbus Children's Research Institute at Children's Hospital, Inc. He is currently Chief Scientific Officer and Executive Vice President at The Children's Hospital of Philadelphia and Professor of Pediatrics at the University of Pennsylvania School of Medicine.

Jack Kay — Chair and Director
Mr. Kay has 45 years' experience in pharmaceutical management and sales, including 27 years with Apotex. He has academic training in business administration from the University of Manitoba and McGill University. Mr. Kay is President and COO of Apotex Inc., and serves on the board of Helix BioPharma Corp., a Toronto and Frankfurt Stock Exchange-listed company. He is Past Chair of the Canadian Generic Pharmaceutical Association and the International Schizophrenia Foundation and the Humber River Regional Hospital in Toronto.

John Langstaff — President, CEO and Director
Dr. Langstaff graduated from the University of Manitoba with a PhD in Microbiology in 1981. He served as Vice President of Operations and Research at ABI Biotechnology and through its evolution to Rh Pharmaceuticals. Dr. Langstaff became President and CEO when Apotex acquired Rh, a role he continued when Rh amalgamated with Cangene in 1995.

J. Robert Lavery^1,2 — Director and Audit Committee Chair
Mr. Lavery, a Chartered Accountant, is President of Shaunnara ULC, an investment management company he has owned since forming the company in 1977. Until his retirement in 2003, Mr. Lavery was also President and CEO of Winpak Ltd., a position he held since co-founding the company in 1977. He continues as a member of the board of directors of Winpak Ltd. and all its subsidiary companies, and is a director of ENSIS Growth Fund Inc., Online Business Systems, and SleeveCo, Inc. Mr. Lavery is on the Advisory Council of Friesen Corporation, and has served on the boards of a number of community healthcare organizations.

R. Scott Lillibridge¹ — Director
Dr. Lillibridge obtained his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, MD. With his extensive training in epidemiology and public health he has spent much of his career in the United States Public Health Service, largely with the U.S. Centers for Disease Control and Prevention (”CDC”). While at the CDC he was the founding Director of the Bioterrorism Preparedness and Response Program. He is currently Assistant Dean, School of Rural Public Health at Texas A&M Health Science Center.

John Vivash² — Director, and Governance & Nominating Committee Chair
Mr. Vivash is President and CEO of Tesseract Financial Inc., positions he's held since founding the financial services consultancy in 1989. Prior to that, he held various senior positions during his lengthy career in the investment community. He has also participated on committees for the Toronto, Montreal and Vancouver Stock Exchanges and the Ontario Securities Commission. He has lectured extensively at the university level, and at business and public conferences. He has also accumulated more than 20 years of board experience. He is on the boards of directors of State Street Trust Company of Canada, The Institute for Intellectual Capital Research, and is Vice Chairman of the Board of Directors of the OCAD University Foundation.

Officers
John Langstaff — President & CEO
William Bees — Senior Vice President, Operations
Paul Brisebois — Vice President, Commercial Development
Michael Graham — Chief Financial Officer
Grant McClarty — Vice President, Research & Development
Francis St. Hilaire — Corporate Counsel & Secretary
Andrew Storey — Vice President, Quality Assurance/Clinical and Regulatory Affairs

1. Member of Audit Committee
2. Member of Governance & Nominating Committee
3. Member of Human Resources & Compensation Committee